Critical revision of the manuscript. All authors read and approved the final manuscript. Competing interests

Critical revision of the manuscript. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 4 January 2011 Accepted: 8 February 2011 Published: 8 February 2011 References 1. Alvarez RH, Kantarjian H, Cortes JE: The biology of Win 63843 price chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007, 44: S4-14. 2. Groffen J, Heisterkamp N: The BCR/ABL hybrid gene. Baillieres Clin Haematol 1987, 1:983-999. 3. Ilaria RL Jr: Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004, 18:525-543, vii. 4. Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817. 5. Druker BJ: Perspectives on the development of imatinib and the future of cancer research. Nat Med 2009, 15:1149-1152. 6. O’Hare T, Eide CA, Deininger MW: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249. 7. Cang S, Liu D: P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008, 1:15. 8. Ernst T, Erben P, Muller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosee P, Hehlmann R, Hochhaus A: Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008, 93:186-192. 9. Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, et al: Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009, 114:5271-5278. 10. Branford S, Melo JV, Hughes TP: Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009, 114:5426-5435. 11. von Bubnoff N, Schneller F, Peschel C, Duyster J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002, 359:487-491. 12. Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY, Park SH: Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol 2009, 27:190-197. 13. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O’Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, et al: Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.5. Conclusion Our single tube AS-PCR method is a simple, rapid, and PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27321907 easy to perform test which requires only simple PCR reagents and a PCR machine leading to overall lower costs as compared to other more complicated and more expensive screening methods. Detection of the most resistant leukemic clone in CML patients undergoing TKI therapy, especially those who reside in the developing worlds, should be feasible with this simple and inexpensive method. Future studies should focus on the design of other primer sets to cover other mutations associated with 2nd generation TKI resistance such as V299L/F317L in dasatinib and E255K/E255V/Y253H in nilotinib.Wongboonma et al. Journal of Hematology Oncology 2011, 4:7 http://www.jhoonline.org/content/4/1/Page 7 of14. Qin Y, Chen S, Jiang B, Jiang Q, Jiang H,.